Aktienanalyse zu Dyne Therapeutics, Inc (DYN)DYNDyne Therapeutics, Inc

Dyne Therapeutics, Inc. is a clinical-stage neuromuscular disease company. It is discovering and advancing therapeutics for people living with genetically driven neuromuscular diseases. Leveraging the modularity of its FORCE platform, it is developing targeted therapeutics that deliver to muscle and central nervous system (CNS). It has a broad pipeline for neuromuscular diseases, including clinical programs for myotonic dystrophy type 1 and Duchenne muscular dystrophy and preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease. Its product candidate, zeleciment basivarsen (also known as DYNE-101), is being evaluated in ACHIEVE, an ongoing Phase I/II global clinical trial in patients with DM1. Its product candidate, zeleciment rostudirsen (also known as DYNE-251), is being evaluated in DELIVER, an ongoing Phase I/II global clinical trial in patients with DMD who have mutations amenable to skipping exon 51. Its other product candidates are DYNE-302 and DYNE-401. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Dyne Therapeutics Inc is a good buy right now due to its recent positive clinical trial data, which showed significant improvements in muscle function for patients with myotonic dystrophy type 1. The stock is currently priced at $16.64, with a notable 5-day price change of +9.47%. Additionally, the RSI is at 60.137, indicating a healthy momentum. However, there is a risk of continued losses, as the company reported a net income loss of $178,556,000 in Q2 2026, which could impact investor sentiment.

8 analysts cover DYN: 4 rate it Buy, 4 Hold and 0 Sell. The average price target is 39.33.